Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 230 people enrolled
- Started
- 1 Jan 2024
- Ended
- 31 Dec 2025
- Type of study
- Observational
- Treatments tested
- Molecular epidemiology of the collection
- Study of the resistome of the S. pettenkoferi population
- Study of the virulome of the S. pettenkoferi population
- Study of the resistance profiles of all S. pettenkoferi isolates
- Selection of strains for in-depth phenotypic study
- Selection of strains (n=3) for the virulence study
- Record updated
- 25 September 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Who cannot take part
- Not applicable for this research on a ready-constituted collection of strains of Staphylococcus pettenkoferi
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gram-positive cocci, particularly Staphylococcus aureus and coagulase-negative staphylococci (SCoN), are the bacteria most frequently isolated from diabetic foot ulcers. Although studies have been carried out on the role of S. aureus in the unfavorable evolution of these wounds, no studies have focused on the role of SCoN. Of the fifty or so SCoN species, not all have the same virulence potential. The role of Staphylococcus pettenkoferi is unknown, yet this bacterium is the 7th most frequently identified in diabetic foot ulcers, suggesting that it may also be involved in the pathophysiology of these infections. At Nîmes University Hospital, this bacterium is mainly identified in samples from diabetic foot ulcers or osteitis in our laboratory and 80% of the bacteria present are in biofilms.It is essential to understand the mechanisms governing these bacterial interactions and establish the true pathogenic potential of these bacteria. Recently, the Nîmes team showed that a strain of S. pettenkoferi (SP165) isolated from foot osteitis in a diabetic patient had real virulence potential. SP165 could not only produce biofilm, but could also survive in human blood, human keratinocytes and murine and human macrophages. It also caused significant embryonic mortality in a zebrafish model. A second study of 29 isolates from Nîmes University Hospital subsequently demonstrated that there were two predominant clones with different virulences. Three biofilm production profiles (rapidly and highly biofilm-producing, slowly biofilm-producing and non-biofilm-producing) and two zebrafish profiles (highly and moderately lethal) were reported by phenotypic and genomic analyses on this panel of strains. Genes for resistance, virulence and biofilm production were also found on their genomes.
Treatments tested
- Molecular epidemiology of the collection
- Study of the resistome of the S. pettenkoferi population
- Study of the virulome of the S. pettenkoferi population
- Study of the resistance profiles of all S. pettenkoferi isolates
- Selection of strains for in-depth phenotypic study
- Selection of strains (n=3) for the virulence study
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of Pathogenicity Factors of Staphylococcus Pettenkoferi in Foot Wounds and Osteitis in Diabetic Patients
- Record updated
- 25 September 2026